CA
NZ
UK
AU
IND
US
…
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Revvity Inc. supplies instruments, reagents, software and services for life-science research, clinical diagnostics and laboratory workflows worldwide. Long-term growth may be supported by rising demand for molecular diagnostics, drug discovery and bioprocessing, recurring consumable sales from an installed base, and broader adoption of genomics and lab automation; investors may find the company attractive for its diversified product mix and recurring-revenue exposure to secular healthcare and research trends.
Key investment risks include sensitivity to cyclical capital and R&D spending, intense competition from larger instrument and reagent suppliers, regulatory and product-approval risk, supply-chain and execution challenges, and concentration in specific end markets.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 268.28M | 316.13M | 182.98M | 651.84M | 1279.89M |
| Net income | 241.68M | 295.83M | -118.38M | 579.18M | 932.16M |
| Selling general administrative | 991.89M | 994.07M | 1015.12M | 1025.51M | 1227.52M |
| Gross profit | 1516.07M | 1322.66M | 1322.19M | 1989.83M | 2851.30M |
| Reconciled depreciation | 405.34M | 427.85M | 430.44M | 427.00M | 358.00M |
| Ebit | 360.46M | 412.40M | 281.79M | 742.70M | 1332.38M |
| Ebitda | 662.72M | 840.25M | 713.56M | 1198.55M | 1745.46M |
| Depreciation and amortization | 302.26M | 427.85M | 431.77M | 455.85M | 413.09M |
| Operating income | 356.63M | 410.52M | 399.49M | 742.70M | 1332.38M |
| Other operating expenses | 2499.42M | 2344.51M | 2351.08M | 2569.12M | 3718.36M |
| Interest expense | 92.19M | 96.28M | 98.81M | 103.95M | 102.13M |
| Tax provision | 28.39M | 33.05M | 76.61M | 129.16M | 347.60M |
| Interest income | 31.10M | 73.19M | 55.33M | 3.59M | 2.24M |
| Net interest income | -61.08M | -23.09M | -41.41M | -100.37M | -99.89M |
| Income tax expense | 25.80M | 33.05M | 3.47M | 129.16M | 347.60M |
| Total revenue | 2856.05M | 2755.03M | 2750.57M | 3311.82M | 5067.17M |
| Total operating expenses | 1159.43M | 912.14M | 922.70M | 1247.13M | 1502.49M |
| Cost of revenue | 1339.99M | 1432.37M | 1428.38M | 1321.99M | 2215.87M |
| Total other income expense net | -88.36M | -94.39M | -216.51M | -90.86M | -52.49M |
| Discontinued operations | - | - | - | 56.50M | 53.72M |
| Net income from continuing ops | 239.88M | 283.07M | 213.43M | 522.68M | 932.28M |
| Net income applicable to common shares | - | - | - | 569.18M | 943.16M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 12168.41M | 12392.48M | 13564.67M | 14126.85M | 15015.55M |
| Intangible assets | 2347.00M | 2640.92M | 3022.32M | 3377.17M | 4063.10M |
| Other current assets | 195.71M | 186.22M | 337.14M | 122.25M | 173.96M |
| Total liab | 4918.05M | 4725.60M | 5691.93M | 6733.98M | 7885.31M |
| Total stockholder equity | 7250.36M | 7666.87M | 7872.74M | 7392.88M | 7130.24M |
| Other current liab | 556.95M | 321.60M | 267.85M | 687.22M | 567.14M |
| Common stock | 112.28M | 120.65M | 123.43M | 126.30M | 126.24M |
| Capital stock | 112.28M | 120.65M | 123.43M | 126.30M | 126.24M |
| Retained earnings | 6054.31M | 5845.22M | 5609.21M | 4951.02M | 4417.17M |
| Other liab | - | - | - | 1109.18M | 1518.43M |
| Good will | 6613.49M | 6463.62M | 6533.55M | 6481.77M | 7416.58M |
| Other assets | - | - | - | 202.97M | 1380.25M |
| Cash | 919.87M | 1163.40M | 913.16M | 454.36M | 618.32M |
| Total current liabilities | 1331.25M | 653.10M | 1450.46M | 1566.50M | 1230.35M |
| Current deferred revenue | - | 140.21M | 135.56M | 135.53M | 303.51M |
| Net debt | 2596.41M | 2162.41M | 3152.13M | 4109.89M | 4551.02M |
| Short term debt | 588.83M | 23.82M | 754.78M | 470.93M | 4.24M |
| Short long term debt | 588.83M | 0.24M | 721.87M | 470.93M | 4.24M |
| Short long term debt total | 3516.28M | 3325.80M | 4065.30M | 4564.24M | 5169.34M |
| Other stockholder equity | 1305.90M | 2097.11M | 2416.79M | 2763.05M | 2749.52M |
| Property plant equipment | - | - | - | 671.30M | 649.57M |
| Total current assets | 2239.75M | 2349.61M | 3001.09M | 3297.82M | 2440.78M |
| Net tangible assets | - | - | - | -2476.07M | -3307.72M |
| Short term investments | - | 0.00M | 689.92M | - | - |
| Net receivables | 744.67M | 632.40M | 632.81M | 612.78M | 1023.79M |
| Long term debt | 2631.24M | 3150.48M | 3177.77M | 3923.35M | 4979.74M |
| Inventory | 379.50M | 367.59M | 428.06M | 405.46M | 624.71M |
| Accounts payable | 185.46M | 167.46M | 204.12M | 272.83M | 355.46M |
| Accumulated other comprehensive income | -222.13M | -396.11M | -276.69M | -447.50M | -162.69M |
| Non currrent assets other | 322.32M | 163.45M | 342.97M | 298.79M | 341.71M |
| Non current assets total | 9928.66M | 10042.87M | 10563.57M | 10829.03M | 12574.77M |
| Capital lease obligations | 178.14M | 175.09M | 165.65M | 169.97M | 185.36M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.08M | 776.16M | 1702.65M | -132.85M | -4112.76M |
| Change to liabilities | - | - | - | -43.80M | -7.58M |
| Total cashflows from investing activities | -17.35M | 776.16M | 1313.52M | -132.85M | -4112.76M |
| Net borrowings | -0.52M | -723.07M | -517.49M | -559.17M | 3073.97M |
| Total cash from financing activities | -855.05M | -1128.23M | -947.12M | -661.80M | 2941.66M |
| Change to operating activities | - | - | - | -236.62M | -57.30M |
| Net income | 241.20M | 283.07M | 179.50M | 579.18M | 932.16M |
| Change in cash | -244.59M | 250.08M | 443.63M | -148.59M | 216.72M |
| Begin period cash flow | 1164.45M | 914.37M | 470.75M | 619.34M | 402.61M |
| End period cash flow | 919.87M | 1164.45M | 914.37M | 470.75M | 619.34M |
| Total cash from operating activities | 581.78M | 628.30M | 91.27M | 679.81M | 1410.75M |
| Issuance of capital stock | - | - | - | 14.11M | - |
| Depreciation | 405.34M | 427.85M | 431.77M | 427.00M | 358.00M |
| Other cashflows from investing activities | 56.55M | 156.90M | 2074.73M | -7.03M | -22.85M |
| Dividends paid | 32.80M | 34.45M | 34.97M | -35.34M | -32.37M |
| Change to inventory | 14.78M | 45.09M | -14.11M | -48.63M | 2.38M |
| Change to account receivables | -101.02M | -15.97M | -9.00M | 66.09M | 155.39M |
| Sale purchase of stock | -820.82M | -369.58M | -388.88M | -80.64M | -73.07M |
| Other cashflows from financing activities | -3.84M | -1.13M | -5.79M | 239.23M | 4959.51M |
| Change to netincome | - | - | - | -60.71M | 18.20M |
| Capital expenditures | 73.52M | 86.65M | 81.37M | 85.63M | 99.89M |
| Change in working capital | -96.78M | -18.30M | -391.35M | -382.11M | 104.36M |
| Stock based compensation | 22.85M | 37.81M | 41.41M | 51.52M | 32.78M |
| Other non cash items | 70.65M | 8.18M | -72.58M | 111.63M | 19.86M |
| Free cash flow | 508.25M | 541.65M | 9.90M | 594.18M | 1310.86M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RVTY Revvity Inc. |
-4.29 2.73% |
152.72 | 61.76 | 21.83 | 5.37 | 1.98 | 5.72 | 21.57 |
| TMO Thermo Fisher Scientific Inc |
-11.46 1.64% |
685.54 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-2.56 1.10% |
229.68 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.25 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.73 3.01% |
23.56 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Prahlad R. Singh Ph.D. | CEO, Pres & Director | 1965 |
| Mr. Tajinder Vohra | Sr. VP of Global Operations | 1966 |
| Mr. Joel S. Goldberg | Sr. VP of Admin., Gen. Counsel & Sec. | 1969 |
| Mr. Daniel R. Tereau | Sr. VP of Strategy & Bus. Devel. | 1968 |
| Mr. Maxwell Krakowiak | Sr. VP & CFO | 1989 |
| Mr. Andrew Okun | VP, Chief Accounting Officer & Treasurer | 1970 |
| Mr. Stephen Barr Willoughby | Sr. VP of Investor Relations & Head of ESG | NA |
| Mr. Robert Francis Friel | Advisor | 1956 |
| Ms. Miriame Victor | Sr. VP & Chief Commercial Officer | 1981 |
| Dr. Masoud Toloue Ph.D. | Sr. VP of Diagnostics | 1980 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.38%
Communication Services
+0.47%
Consumer Cyclical
+1.35%
Consumer Defensive
+0.87%
Energy
-2.31%
Financial Services
+1.00%
Financials
+0.52%
Healthcare
-0.64%
Industrials
+0.62%
Real Estate
+0.65%
Technology
-0.08%
Utilities
+0.01%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...